Curaleaf Holdings’ valuation
The chart above compares Curaleaf Holdings’ valuation multiples with those of its peers. Let’s explore the valuation multiples and market caps of Curaleaf and a few of its competitors.
Curaleaf was trading at a forward PE multiple of ~103.8x on November 26 compared to the industry average of ~44.5x, while its competitor Trulieve (TCNNF) was trading at a forward PE multiple of 21.4x.
Since analysts expect Curaleaf’s EBITDA to be negative in the coming months, its forward EV-to-EBITDA (enterprise value-to-EBITDA) multiple is negative. Competitors WeedMD and Maricann are trading at forward EV-to-EBITDA multiples of 6.7x and 20.8x, respectively.
Curaleaf Holdings’ market cap as of November 27 is $2.14 billion, and it has 335.1 million shares outstanding in OTC markets. About 99.7% of these shares are free floating. Also, the top ten shareholders hold ~0.31% of the company’s total shares.
The market caps of WeedMD, Trulieve, and Maricann are $121.0 million, $94.7 million, and $195.2 million, respectively.
The Horizons Marijuana Life Sciences ETF (HMMJ) invests in companies in the cannabis industry. It holds ~0.8% in Maricann and 0.5% in WeedMD.